2nd Apr 2012 15:00
Annual Information Update
April 2, 2012 - Shire plc , the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2011 and March 31, 2012 (save for the final item under section 3 below which has been deemed as having been filed on March 31, 2011).
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
1. Announcements made via a RIS
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
30-Mar-12 Shire Announces Top-line Results of the PREVENT2 Trial 22-Mar-12 2011 Annual Report - DTR 6.3.5 Disclosure 15-Mar-12 Shire to acquire FerroKin BioSciences, Inc. 15-Mar-12 Shire Update on US BLA Filing for REPLAGAL® 06-Mar-12 PDMR Share Dealing 01-Mar-12 Total Voting Rights 01-Mar-12 Elections for Interim Dividend 29-Feb-12 Director/PDMR Share Dealings 28-Feb-12 PDMR Share Dealing 27-Feb-12 Director Declaration 24-Feb-12 PDMR Share Dealings 23-Feb-12 PDMR Share Dealings 22-Feb-12 Director/PDMR Share Dealings 09-Feb-12 Another strong year for Shire 01-Feb-12 Total Voting Rights 31-Jan-12 Full Year 2011 results date notification - Feb 9, 2012 23-Jan-12 Holding(s) in Company 05-Jan-12 VENVANSE Marketing Application accepted for review in EU 03-Jan-12 Total Voting Rights 30-Dec-11 Director/PDMR Shareholding 15-Dec-11 Shire plc Board and Committee Changes 14-Dec-11 Director/PDMR Shareholding 12-Dec-11 Director/PDMR Shareholding 01-Dec-11 Total Voting Rights 01-Dec-11 Director/PDMR Shareholding 24-Nov-11 Block listing six monthly return 21-Nov-11 Director/PDMR Shareholding 07-Nov-11 Director/PDMR Shareholding 02-Nov-11 PDMR Share Transactions 01-Nov-11 Total Voting Rights 01-Nov-11 Director Declaration 28-Oct-11 Continued strong product sales performance in Q3 13-Oct-11 3rd Quarter Results Notification 03-Oct-11 Total Voting Rights 30-Sep-11 Director/PDMR Shareholding 26-Sep-11 Director/PDMR Shareholding 01-Sep-11 Elections for Interim Dividend 01-Sep-11 Total Voting Rights 25-Aug-11 Regulatory Approval 12-Aug-11 Purchase of Shares by Employee Benefit Trust 11-Aug-11 Half Yearly Report 03-Aug-11 Director/PDMR Shareholding 02-Aug-11 Director/PDMR Shareholding 01-Aug-11 Director/PDMR Shareholding 01-Aug-11 Total Voting Rights 29-Jul-11 Holding(s) in Company 28-Jul-11 Shire's quarterly revenues grow by 25% 27-Jul-11 Board Changes 15-Jul-11 Second quarter 2011 results date notification 07-Jul-11 Shire files lawsuit against Watson and Roxane 01-Jul-11 Shire files lawsuit against Sandoz and Amneal 01-Jul-11 Total Voting Rights 28-Jun-11 Shire completes acquisition of Advanced BioHealing, Inc. 24-Jun-11 Purchase of Shares by Employee Benefit Trust 21-Jun-11 Director/PDMR Shareholding 17-Jun-11 Director/PDMR Shareholding 01-Jun-11 Total Voting Rights 25-May-11 Shire receives VYVANSE(R) Paragraph IV Notice Letters 24-May-11 Block listing - Six Monthly Return 19-May-11 Shire receives VYVANSE(R) Paragraph IV Notice Letter 18-May-11 Shire to acquire Advanced BioHealing 09-May-11 Director/PDMR Shareholding 06-May-11 Purchase of Shares by Employee Benefit Trust 04-May-11 Director Declaration 03-May-11 Total Voting Rights 28-Apr-11 Shire delivers a strong first quarter performance
26-Apr-11 Result of AGM 20-Apr-11 Notice of Results
19-Apr-11 Holding(s) in Company 06-Apr-11 Shire files lawsuit against Watson Pharmaceuticals 01-Apr-11 Director/PDMR Shareholding 01-Apr-11 Total Voting Rights 01-Apr-11 Annual Information Update
2. Documents filed with the Securities and Exchange Commission ("SEC")
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC's website at www.sec.gov.
3. Documents filed with Companies Registry, Jersey
Date of Delivery Document
24-Feb-12 Annual Return
17-May-11 Special Resolutions passed on April 26, 2011
31-Mar-11 Annual Report and Accounts for the year ended December 31, 2010
4. Documents sent to Shareholders
The following documents were published and sent to shareholders, and are available on the Company's website.
Date of Delivery Document
22-Mar-12 Annual Report and Accounts for the year ended December 31, 2011
22-Mar-12 Notice of 2012 Annual General Meeting
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company's registered office.
Tony GuthrieDeputy Company Secretary
For further information please contact:
Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
XLONRelated Shares:
Shire